Drug repositioning and repurposing for Alzheimer disease
Ballard, C; Aarsland, D; Cummings, J; et al.O'Brien, J; Mills, R; Molinuevo, JL; Fladby, T; Williams, G; Doherty, P; Corbett, A; Sultana, J
Date: 16 September 2020
Article
Journal
Nature Reviews Neurology
Publisher
Nature Research
Publisher DOI
Abstract
Drug repositioning and repurposing can enhance traditional drug development efforts and could
accelerate the identification of new treatments for individuals with Alzheimer disease (AD) dementia
and mild cognitive impairment. Transcriptional profiling offers a new and highly efficient approach
to the identification of novel ...
Drug repositioning and repurposing can enhance traditional drug development efforts and could
accelerate the identification of new treatments for individuals with Alzheimer disease (AD) dementia
and mild cognitive impairment. Transcriptional profiling offers a new and highly efficient approach
to the identification of novel candidates for repositioning and repurposing. In the future, novel AD
transcriptional signatures from cells isolated at early stages of disease, or from human neurons or
microglia that carry mutations that increase risk of AD, might be used as probes to identify
additional candidate drugs. Phase II trials assessing repurposed agents must consider the best target
population for a specific candidate therapy as well as the mechanism of action of the treatment. In
this Review, we highlight promising compounds to prioritise for clinical trials in individuals with AD,
and discuss the value of Delphi consensus methodology and evidence-based reviews to inform this
prioritization process. We also describe emerging work, focussing on the potential value of transcript
signatures as a cost-effective approach to identify novel candidates for repositioning.
Institute of Health Research
Collections of Former Colleges
Item views 0
Full item downloads 0